BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30924085)

  • 1. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
    Pitoia F; Abelleira E; Cross G
    Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
    Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
    Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
    Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
    Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
    Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
    Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
    [No Abstract]   [Full Text] [Related]  

  • 11. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
    Tian T; Kou Y; Huang R; Liu B
    Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer.
    Liu L; Zhang X; Tian T; Huang R; Liu B
    Thyroid; 2020 Jul; 30(7):1017-1024. PubMed ID: 31964278
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.
    Miyauchi A; Kudo T; Miya A; Kobayashi K; Ito Y; Takamura Y; Higashiyama T; Fukushima M; Kihara M; Inoue H; Tomoda C; Yabuta T; Masuoka H
    Thyroid; 2011 Jul; 21(7):707-16. PubMed ID: 21649472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
    Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 18. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
    Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
    Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
    Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine.
    Matrone A; Faranda A; Latrofa F; Gambale C; Stefani Donati D; Molinaro E; Agate L; Viola D; Piaggi P; Torregrossa L; Basolo F; Elisei R
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32453405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.